Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
133 studies found for:    folate receptor
Show Display Options
Rank Status Study
1 Unknown  The Development of Human Immunologic Assays Specific to Folate Receptor Antigen
Condition: Ovarian Cancer
Intervention: Procedure: venous puncture
2 Unknown  Measurement of the Folate Receptor in Blood
Condition: Healthy
Intervention:
3 Active, not recruiting Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Conditions: Epilepsy;   Psychiatric or Mood Diseases or Conditions
Intervention:
4 Unknown  FR in Stored Plasma
Condition: Ovarian Cancer
Intervention:
5 Completed Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Technetium Tc 99m EC20
6 Recruiting Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: folate receptor alpha-loaded dendritic cell vaccine;   Other: laboratory biomarker analysis
7 Active, not recruiting Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Breast Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: cyclophosphamide;   Biological: multi-epitope folate receptor alpha peptide vaccine;   Other: laboratory biomarker analysis
8 Active, not recruiting Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145;   Drug: EC145 + Docetaxel;   Drug: Docetaxel;   Drug: EC20
9 Completed A Study of MORAb-003 in Patients With Solid Tumor
Condition: Patients With a Folate-receptor Alpha Expressing Solid Tumor Who Are Not Responsive or Resistant to Standard Therapy and Have no Other Appropriate Treatment.
Intervention: Drug: MORAb-003
10 Active, not recruiting
Has Results
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab
11 Recruiting A Folinic Acid Intervention for Autism Spectrum Disorders
Conditions: Autism Spectrum Disorder;   Autistic Disorder;   Autism;   Asperger's Syndrome;   Pervasive Development Disorders
Interventions: Drug: Folinic Acid and placebo;   Drug: Folinic Acid
12 Completed Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: radionuclide imaging;   Radiation: indium In 111 folic acid
13 Completed Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
Conditions: Ovarian Carcinoma;   Recurrent Endometrial Carcinoma
Intervention: Drug: Tc 99m EC20
14 Completed Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Conditions: Recurrent or Metastatic Cancer;   Head and Neck Cancer;   Pancreas Cancer;   Bladder Cancer;   Testicular Cancer
Intervention: Drug: Tc 99m EC20
15 Completed Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Tc 99m EC20
16 Completed Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Condition: Pituitary Tumors
Intervention: Drug: Technetium Tc 99m EC20
17 Terminated Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer
Intervention: Drug: Gemzar and Alimta
18 Recruiting Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)
Condition: Resectable Breast Cancer
Intervention: Drug: EC17
19 Terminated Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Condition: Ovarian Cancer
Intervention: Drug: EC-17
20 Terminated An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Dietary Supplement: Folic Acid, Vitamin B6, Vitamin B12;   Dietary Supplement: B6, B12, L-methylfolate;   Dietary Supplement: B6, B12, Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years